Handbook of hematologic malignancies

571 Pages·2021·35.646 MB·English

by  MD Ling Zhang (editor), Ateefa Chaudhury (editor), Johnny Nguyen (editor), David A. Sallman (editor)

Handbook of
SECOND
EDITION
Hematologic Malignancies An Imprint of Springer Publishing
H
SECOND EDITION a
n
d
David A. Sallman, MD • Ateefa Chaudhury, MD b Handbook of
o
Johnny Nguyen, MD • Ling Zhang, MD o
k

This revised and updated second edition of Handbook of Hematologic Malignancies continues to be o
f
an essential and go-to resource for the busy hematologist, hematologic oncologist, hematopathologist,
H Hematologic
oncology advanced practice provider, oncology nurse, and trainee. Concisely organized, each chapter
e
provides the most current, need-to-know points of diagnosis, prognosis, therapeutic management, m
and clinical trial opportunities for each hematologic malignancy. Chapters are complete with richly a
illustrated figures to highlight the hematopathologic characteristics of diseases in addition to helpful t
o
tables on differential diagnosis, prognostic scoring systems, molecular profiles, and therapeutic options. l
o Malignancies
A new case-based chapter concludes the handbook with clinical cases designed to test a clinician’s
g
knowledge of pathologic diagnosis and clinical presentation of diseases covered in the book. With over i
c
twenty new FDA-approved indications since publication of the first edition, including breakthroughs with

CAR-T therapy and other evidence-based treatment options for patients with hematologic disease, this M
book serves as a quick reference to practice-changing information on challenging diagnostic dilemmas, a
l
frontline and refractory treatment scenarios, and more. i
g SECOND EDITION
The subspecialty field of hematologic oncology is ever-changing and expanding with available treatment n
a
options, and this second edition keeps the busy clinician abreast of recent findings and their impact on
n
evidence-based treatment and management. Written by experienced clinicians at the world-renowned c
Moffitt Cancer Center in Tampa, Florida, and including contributions from leading academicians, i
e
hematologists, and oncologists throughout the country, this unique handbook is packed with authoritative s
knowledge and clinical insight into all known hematologic cancers.
KEY FEATURES: N S
G A
U L
n Includes seven new chapters covering CAR-T and novel therapeutic options Y L
including CD19 CAR T-cell therapy, novel cellular therapies, cytokine release E M
syndrome, cancer-associated thrombosis, and more N A
N
n Cstoamndparirsdess o cf ocmarpea acnt da nmda unpadgaetmede ndti sceoansseid-seirtaet ciohnasp tine rbsu dlleest cproibinintg f onremwa t • ZH • C
n Highlights important diagnostic tools that assist with conducting key A H
differential diagnoses and unveiling answers to diagnostic dilemmas N A
n Provides updates of potential practice-changing clinical trials and G UD
paradigm-shifting treatment considerations in each disease-based chapter H
n Purchase includes digital access for use on most mobile devices or U DAVID A. SALLMAN
computers R
Y
ATEEFA CHAUDHURY
Recommended
Shelving Category: JOHNNY NGUYEN
Oncology
LING ZHANG
11 W. 42nd Street
New York, NY 10036-8002
www.springerpub.com
Handbook of
Hematologic Malignancies

Handbook of
Hematologic Malignancies
Second Edition
Editors
David A. Sallman, MD
Assistant Member, Department of Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
University of South Florida Morsani College of Medicine
Tampa, Florida
Ateefa Chaudhury, MD
Hematologist, New Mexico Cancer Center
Albuquerque, New Mexico
Johnny Nguyen, MD
Assistant Professor, Anatomic Pathology Lab
Johns Hopkins All Children’s Hospital
Baltimore, Maryland
Ling Zhang, MD
Senior Member, Professor, Department of Pathology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
New York
Copyright © 2021 Springer Publishing Company, LLC
Demos Medical Publishing is an imprint of Springer Publishing Company.
All rights reserved.
First Springer Publishing edition 2016.
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the
prior permission of Springer Publishing Company, LLC, or authorization through payment of the
appropriate fees to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923,
978-750-8400, fax [phone], [email protected] or on the Web at www.copyright.com.
Springer Publishing Company, LLC
11 West 42nd Street, New York, NY 10036
www.springerpub.com
connect.springerpub.com/
Acquisitions Editor: David D’Addona
Compositor: Transforma
ISBN: 978-0-8261-4976-3
e-book ISBN: 978-0-8261-4977-0
DOI: 10.1891/9780826149770
Supplemental Clinical Cases are available from https://connect.springerpub.com/content/
book/978-0-8261-4977-0.
Clinical Case Material ISBN: 978-0-8261-4978-7
20 21 22 23 24 / 5 4 3 2 1
Medicine is an ever-changing science. Research and clinical experience are continually expanding our
knowledge, in particular our understanding of proper treatment and drug therapy. The authors,
editors, and publisher have made every effort to ensure that all information in this book is in
accordance with the state of knowledge at the time of production of the book. Nevertheless, the
authors, editors, and publisher are not responsible for any errors or omissions or for any conse-
quence from application of the information in this book and make no warranty, expressed or implied,
with respect to the content of this publication. Every reader should examine carefully the package
inserts accompanying each drug and should carefully check whether the dosage schedules therein or
the contraindications stated by the manufacturer differ from the statements made in this book. Such
examination is particularly important with drugs that are either rarely used or have been newly
released on the market.
Library of Congress Cataloging-in-Publication Data
Names: Sallman, David A., editor. | Chaudhury, Ateefa, editor. | Nguyen, Johnny, editor. |
Zhang, Ling, MD editor.
Title: Handbook of hematologic malignancies / editors, David A. Sallman, Ateefa Chaudhury,
Johnny Nguyen, Ling Zhang.
Description: Second edition. | New York, NY : Springer Publishing Company, LLC, [2021] |
Includes bibliographical references and index. | Summary: "The 2nd edition of Handbook
of Hematologic Malignancies encompasses the hard work and effort of many fellows and
residents, working under the mentorship and guidance of attending staff physicians at
world-renowned cancer centers throughout the country, not only at Moffitt Cancer
Center, but also many others including Harvard, Mayo Clinic, and Memorial Sloan Kettering
Cancer Center. Specifically, the editors would like acknowledge Dr. Kenian Liu from
the Cytogenetic Laboratory (Moffitt) for providing FISH images and Drs. Lugen Chen
(Tampa General Hospital), Wilfredo Chamizo (All Children Hospital at St Petersburg),
Haipeng Shao (Moffitt), Xiaohui Zhang (Moffitt), and Jane Messina (Moffitt) for sharing
unique cases to the book. The quality of their work and their willingness to contribute to
make this textbook one that can serve the needs of readers across disciplines, made
working on this project a rewarding experience for us all"-- Provided by publisher.
Identifiers: LCCN 2020038913 (print) | LCCN 2020038914 (ebook) | ISBN 9780826149763 (paperback) |
ISBN 9780826149770 (ebook)
Subjects: MESH: Hematologic Neoplasms | Handbook
Classification: LCC RC280.H47 (print) | LCC RC280.H47 (ebook) | NLM WH 39
| DDC 616.99/418--dc23
LC record available at https://lccn.loc.gov/2020038913
LC ebook record available at https://lccn.loc.gov/2020038914
Contact us to receive discount rates on bulk purchases. We can also customize our books to meet
your needs.
For more information please contact: [email protected]
Publisher’s Note: New and used products purchased from third-party sellers are not guaranteed for
quality, authenticity, or access to any included digital components.
Printed in the United States of America.
Contents
Contributors xi
Preface xix
Abbreviations xxi
Part I. INTRODUCTION AND OVERVIEW
1. Normal Hematopoiesis and Diagnosis Algorithms for
Cytopenias and Cytoses 1
Onyee Chan and Ling Zhang
2. Familial/Inherited Mutations and Risks of Hematologic
Malignancies 11
Sophia C. Korotev, Lucy A. Godley, and Amy M. Trottier
3. Diagnostic Approaches to Hematologic Malignancies 17
Johnny Nguyen, Rohit Sharma, and Ling Zhang
4. Minimal Residual Disease Assays 39
Pukhraz Basra and Silvia Tse Bunting
Part II. MYELOPROLIFERATIVE NEOPLASMS
5. Polycythemia Vera 45
Misty Dawn Shields and Kenneth S. Zuckerman
6. Essential Thrombocythemia 51
Nikesh N. Shah and Kenneth S. Zuckerman
7. Primary Myelofibrosis 61
Carmelo J. Blanquicett and Andrew Kuykendall
8. Chronic Myelogenous Leukemia 69
Chetasi Talati, Dasom Caroline Lee, and Javier Pinilla-Ibarz
9. Chronic Neutrophilic Leukemia 77
Yenny Alejandra Moreno Vanegas, Arun Kadamkulam Syriac,
and Utkarsh Acharya
vi CONTENTS
10. Systemic Mastocytosis 83
Kristen Gonter-Aubin and Andrew Kuykendall
11. PDGFRA/PDGFRB/FGFR1 Myeloid Neoplasms 89
Joseph Clara and Eric Padron
Part III. MYELODYSPLASTIC AND BONE MARROW FAILURE
SYNDROMES
12. Myelodysplastic Syndromes 95
Anthony M. Hunter, David A. Sallman, and Rami Komrokji
13. Aplastic Anemia 103
Jae Chung and Rami Komrokji
14. Paroxysmal Nocturnal Hemoglobinuria 109
Hilda Ding
Part IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS
15. Myelodysplastic/Myeloproliferative Overlap Syndromes 115
Virginia O. Volpe, Jennifer Eatrides, and Eric Padron
16. Chronic Myelomonocytic Leukemia 121
Alexandra Gomez-Arteaga and Justin M. Watts
Part V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES
17. Acute Myeloid Leukemia 129
David M. Swoboda and Kendra Sweet
18. Secondary AML and AML-MRC 135
Seongseok Yun, David A. Sallman, and Jeffrey E. Lancet
19. Acute Promyelocytic Leukemia 141
Virginia O. Volpe and Jeffrey E. Lancet
20. Blastic Plasmacytoid Dendritic Cell Neoplasm 149
Justin Taylor and Andrew A. Lane
Part VI. ACUTE LYMPHOID LEUKEMIA
21. B-Lymphoblastic Leukemia/Lymphoma 155
Fernando Vargas and Bijal Shah
22. BCR-ABL1+ B-Lymphoblastic Leukemia 165
Yehuda Deutsch and Bijal Shah
CONTENTS vii
23. T-Cell Acute Lymphoblastic Leukemia/Lymphoma 171
Muhammad Sardar, Ravitharan Krishnadasan,
and Keri Maher
Part VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
24. Acute Leukemia of Ambiguous Lineage 177
Muhammad Sardar, Ravitharan Krishnadasan,
and Keri Maher
Part VIII. MATURE T- AND NK-CELL LEUKEMIA
25. T-Cell Prolymphocytic Leukemia 181
Pei Zhang and Abhijeet Kumar
26. T-Cell Large Granular Lymphocytic Leukemia 185
Ning Dong, Magali Van den Bergh, and Lubomir Sokol
27. Aggressive Natural Killer Cell Leukemia 191
Emilie Wang, Mintallah Haider, and Lubomir Sokol
Part IX. PLASMA CELL DISORDERS
28. Monoclonal Gammopathy of Unknown Significance,
Smoldering Myeloma, and Plasmacytomas 197
Hannah Asghari and Brandon Blue
29. Multiple Myeloma 205
Shonali Midha, Patrick Griffin, and Rachid Baz
30. Waldenström Macroglobulinemia 219
Ariel Grajales-Cruz and Rachid Baz
31. Immunoglobulin Light Chain Amyloidosis 229
Taxiarchis Kourelis and Morie A. Gertz
Part X. HODGKIN LYMPHOMA
32. Hodgkin Lymphoma 235
Anju Nair
Part XI. NON-HODGKIN LYMPHOMA
33. Diagnosis and Classification of Non-Hodgkin Lymphomas 243
Johnny Nguyen, Haipeng Shao, and Ling Zhang
viii CONTENTS
Part XII. MATURE B-CELL LYMPHOMA
Very Aggressive
34. Burkitt Lymphoma 249
Anju Nair
Aggressive
35. Diffuse Large B-Cell Lymphoma 255
Jose D. Sandoval-Sus and Julio C. Chavez
36. Double-Hit Lymphoma 263
Nikhil Mukhi
37. Mantle Cell Lymphoma 267
Ruchi Desai and Bijal Shah
38. Primary Mediastinal Large B-Cell Lymphoma 273
Vania Phuoc, Andreas Saltos, and Julio C. Chavez
39. Primary Central Nervous System Lymphoma 279
Tony Kurian, Liliana Bustamante, Peter Forsyth,
and Solmaz Sahebjam
40. HIV-Related Lymphomas 287
Danny Nguyen, Nishan Tchekmedyian, and
Jeremy S. Abramson
Indolent
41. Follicular Lymphoma 295
Jori Kaplan and Celeste Bello
42. Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma 303
Emilie Wang, Ateefa Chaudhury, and
Javier Pinilla-Ibarz
43. Hairy Cell Leukemia 311
Justin Taylor and Omar Abdel-Wahab
44. Marginal Zone Lymphoma 317
Nishan Tchekmedyian, Danny Nguyen, Hayder Saeed,
and Celeste Bello
45. Mucosa-Associated Lymphoid Tissue Lymphoma 323
Nishan Tchekmedyian, Danny Nguyen,
and Hayder Saeed
CONTENTS ix
Part XIII. MATURE T- AND NK-CELL LYMPHOMA
46. Adult T-Cell Leukemia/Lymphoma 331
Nikhil Mukhi and Lubomir Sokol
47. Anaplastic Large Cell Lymphoma 337
Poorvi Desai, Ling Zhang, and Lubomir Sokol
48. Extranodal Natural Killer/T-Cell Lymphoma 343
Joseph Clara and Lubomir Sokol
49. Mycosis Fungoides 351
Vania Phuoc and Lubomir Sokol
50. Hepatosplenic T-Cell Lymphoma 359
Walter Hanel and Narendranath Epperla
Part XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS
51. Langerhans Cell Histiocytosis, Erdheim-Chester Disease,
Rosai-Dorfman Disease, and Histiocytic Sarcoma 367
Sameem Abedin and Ehab Atallah
52. Hemophagocytic Lymphohistiocytosis 375
Hilda Ding and Lubomir Sokol
Part XV. BONE MARROW TRANSPLANTATION
53. Autologous Hematopoietic Cell Transplantation 383
Hemant S. Murthy and Mohamed A. Kharfan-Dabaja
54. Allogeneic Hematopoietic Cell Transplantation 393
Hemant S. Murthy, Taiga Nishihori, and
Mohamed A. Kharfan-Dabaja
Part XVI. NEW CELLULAR IMMUNOTHERAPY
55. CAR-T Overview and Novel Cellular Therapeutic Options,
Including TCR Gene Transfers 407
Cristian I. Rodríguez Arocho, Marco L. Davila, and
David A. Sallman
56. CD19 CAR T-Cell Therapy 415
Michael D. Jain, Brigett D. Brandjes, and Frederick L. Locke
57. Cytokine Release Syndrome and Other Toxicities Associated
With Novel Cellular Therapies 421
Jennifer M. Logue, Estelle Cervantes, Christina A. Bachmeier,
and Marco L. Davila